These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

106 related articles for article (PubMed ID: 17062700)

  • 1. Polyclonal resistance in gastrointestinal stromal tumor treated with sequential kinase inhibitors.
    Loughrey MB; Waring PM; Dobrovic A; Demetri G; Kovalenko S; McArthur G
    Clin Cancer Res; 2006 Oct; 12(20 Pt 1):6205-6; author reply 6206-7. PubMed ID: 17062700
    [No Abstract]   [Full Text] [Related]  

  • 2. Current management of GIST.
    Blanke C
    Clin Adv Hematol Oncol; 2004 May; 2(5):280, 283. PubMed ID: 17682286
    [No Abstract]   [Full Text] [Related]  

  • 3. Gastrointestinal stromal tumors (GISTs): a pathology view point.
    Sornmayura P
    J Med Assoc Thai; 2009 Jan; 92(1):124-35. PubMed ID: 19260254
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pathological response of gastrointestinal stromal tumour to imatinib treatment correlates with tumour KIT mutational status in individual tumour clones.
    Loughrey MB; Beshay V; Dobrovic A; Zalcberg J; Waring PM
    Histopathology; 2006 Jul; 49(1):99-100. PubMed ID: 16842259
    [No Abstract]   [Full Text] [Related]  

  • 5. Rhabdomyosarcomatous differentiation in gastrointestinal stromal tumors after tyrosine kinase inhibitor therapy: a novel form of tumor progression.
    Liegl B; Hornick JL; Antonescu CR; Corless CL; Fletcher CD
    Am J Surg Pathol; 2009 Feb; 33(2):218-26. PubMed ID: 18830121
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Is there a role for neoadjuvant treatment with Gleevec for large rectal gastrointestinal stromal tumors?
    Wasserberg N; Nunoo-Mensah JW; Beart RW; Ker TS
    Int J Colorectal Dis; 2007 Aug; 22(8):981-2. PubMed ID: 16583196
    [No Abstract]   [Full Text] [Related]  

  • 7. KIT mutations and imatinib dose effects in patients with gastrointestinal stromal tumors.
    De Giorgi U
    J Clin Oncol; 2007 Mar; 25(9):1146-7; author reply 1147-8. PubMed ID: 17369583
    [No Abstract]   [Full Text] [Related]  

  • 8. Secondary C-kit mutation is a cause of acquired resistance to imatinib in gastrointestinal stromal tumor.
    Zheng S; Pan YL; Tao DY; Wang JL; Huang KE
    Scand J Gastroenterol; 2009; 44(6):760-3. PubMed ID: 19096980
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Protein modelling of a novel KIT mutation (N567Y) in the gastrointestinal stromal tumour.
    Alyuruk H; Calibasi G; Cavas L; Baskin Y; Oztop I; Ellidokuz H; Yilmaz U
    Eur J Cancer; 2013 Jul; 49(10):2449-52. PubMed ID: 23588081
    [No Abstract]   [Full Text] [Related]  

  • 10. Could imatinib replace surgery in esophageal gastrointestinal stromal tumor.
    Al-Salam S; El-Teraifi HA; Taha MS
    Saudi Med J; 2006 Aug; 27(8):1236-9. PubMed ID: 16883460
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Gastrointestinal stromal tumor: a clinical overview.
    Quek R; George S
    Hematol Oncol Clin North Am; 2009 Feb; 23(1):69-78, viii. PubMed ID: 19248971
    [TBL] [Abstract][Full Text] [Related]  

  • 12. c-Kit/PDGFRA gene status alterations possibly related to primary imatinib resistance in gastrointestinal stromal tumors.
    Miselli FC; Casieri P; Negri T; Orsenigo M; Lagonigro MS; Gronchi A; Fiore M; Casali PG; Bertulli R; Carbone A; Pierotti MA; Tamborini E; Pilotti S
    Clin Cancer Res; 2007 Apr; 13(8):2369-77. PubMed ID: 17438095
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Gastrointestinal stromal tumors II: medical oncology and tumor response assessment.
    Benjamin RS; Debiec-Rychter M; Le Cesne A; Sleijfer S; Demetri GD; Joensuu H; Schöffski P; Poveda A
    Semin Oncol; 2009 Aug; 36(4):302-11. PubMed ID: 19664491
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Treatment of metastatic gastrointestinal stromal tumors with Imatinib: report of four cases].
    Garrido S M; Moneada M M; Tapia N G; Méndez O G; Galindo A H; Huete G A; Ibáñez A L; González S; Alvarez Z M
    Rev Med Chil; 2007 Oct; 135(10):1327-32. PubMed ID: 18180842
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Successes and challenges in translational research: the development of targeted therapy for gastrointestinal stromal tumours.
    Renouf DJ; Wilson L; Blanke CD
    Clin Cancer Res; 2009 Jun; 15(12):3908-11. PubMed ID: 19509180
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Double resistance to imatinib and AMG 706 caused by multiple acquired KIT exon 17 mutations in a gastrointestinal stromal tumour.
    Grabellus F; Ebeling P; Worm K; Sheu SY; Antoch G; Frilling A; Schmid KW
    Gut; 2007 Jul; 56(7):1025-6. PubMed ID: 17566038
    [No Abstract]   [Full Text] [Related]  

  • 17. Pathologic and molecular heterogeneity in imatinib-stable or imatinib-responsive gastrointestinal stromal tumors.
    Agaram NP; Besmer P; Wong GC; Guo T; Socci ND; Maki RG; DeSantis D; Brennan MF; Singer S; DeMatteo RP; Antonescu CR
    Clin Cancer Res; 2007 Jan; 13(1):170-81. PubMed ID: 17200352
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Kinase mutations and imatinib mesylate response for 64 Taiwanese with advanced GIST: preliminary experience from Chang Gung Memorial Hospital.
    Yeh CN; Chen TW; Lee HL; Liu YY; Chao TC; Hwang TL; Jan YY; Chen MF
    Ann Surg Oncol; 2007 Mar; 14(3):1123-8. PubMed ID: 17195905
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clinical update on adult and pediatric gastrointestinal stromal tumor. Preface.
    Trent JC; Patel SR
    Hematol Oncol Clin North Am; 2009 Feb; 23(1):xiii-xiv. PubMed ID: 19248966
    [No Abstract]   [Full Text] [Related]  

  • 20. [Activating mutations in receptor tyrosine kinases with relevance for treatment of gastrointestinal stromal tumors].
    Wardelmann E; Merkelbach-Bruse S; Büttner R; Schildhaus HU
    Verh Dtsch Ges Pathol; 2007; 91():165-8. PubMed ID: 18314611
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.